Icon Cancer Center Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2021
NCT04964375
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Icon Cancer Center | ICON Cancer Centre | Icon Cancer Centre South Brisbane

Active Ingredients

Drugs in Phase 1 Trials (4)

absk043 (1 trial)

amt-116 car-t cells (1 trial)

amt-151 (1 trial)

awt020 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Melanoma (Phase 3)

Neoplasm Metastasis (Phase 3)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 4
  • # of Trial APIs: 4